A pilot study: (131)I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically created resection cavity (SCRC) to achieve a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Reardon, David A., Zalutsky, Michael R., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Herndon, James E., McLendon, Roger E., Pegram, Charles N., Quinn, Jennifer A., Rich, Jeremy N., Vredenburgh, James J., Desjardins, Annick, Guruangan, Sridharan, Boulton, Susan, Raynor, Renee H., Dowell, Jeanette M., Wong, Terence Z., Zhao, Xiao-Guang, Friedman, Henry S., Bigner, Darell D.
Format: Artigo
Langue:Inglês
Publié: Duke University Press 2008
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613820/
https://ncbi.nlm.nih.gov/pubmed/18287339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2007-053
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires